In this article, we will look at the 9 Best Drug Stocks to Buy According to Analysts.
On April 27, Jurrien Timmer, director of global macro at Fidelity Investments, appeared on CNBC to talk about the market and oil prices, and how necessary it is for oil prices to retreat from their highs, among other things.
He was of the view that there is not a lot the Fed can do about a supply shock, as if there was a demand shock from fiscal stimulus, like what we saw in 2020 and 2021, it would have been a different story. The Fed acknowledged that it is powerless over a supply shock, and so raising rates just because oil prices are up does not serve much of a purpose. On the other hand, he also stated that cutting rates three more times, which is what was expected earlier this year, is not in the cards either. It is not needed as well, as the economy is running pretty well.
READ ALSO: 10 Best Booming Stocks to Buy According to Hedge Funds AND 8 Best Stem Cell Therapy Stocks to Buy.
Timmer further stated in terms of the market and oil prices that the market has moved on already, but the oil prices are still near $100, and so we have not had that round trip yet. That, according to him, is something that needs to happen before the markets can really and completely declare victory.
With these broader market trends in view, let’s look at the best drug stocks to buy according to analysts.
Our Methodology
We used the Finviz stock screener to make a list of the best drug stocks that analysts are bullish on and picked the top 9 with the highest number of hedge fund holders, as of Q4 2025. We sourced the hedge fund sentiment data from Insider Monkey’s database.
Note: All data was recorded on April 28.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
9 Best Drug Stocks to Buy According to Analysts
9. Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) is one of the best drug stocks to buy according to analysts. Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) was downgraded to Hold from Buy by Jefferies on April 20, with the firm bringing the price target on the stock down to $22 from $30. Despite what it calls an “inexpensive valuation”, the firm cited new launches being “less impactful than expected” and a lack of meaningful upside catalysts for the downgrade.
For additional perspective, in its financial results for the three months and full year ended December 31, 2025, Amphastar Pharmaceuticals, Inc. reported net revenues of $183.1 million and $719.9 million, respectively. GAAP net income was $24.4 million, or $0.51 per share, and $98.1 million, or $2.03 per share, respectively, for fiscal Q4 and the full year. Management further reported that the adjusted non-GAAP net income came up to $34.2 million, or $0.73 per share, and $156.6 million, or $3.25 per share, respectively, for the quarter and full year.
Amphastar Pharmaceuticals, Inc. develops, manufactures, markets, and sells technically challenging generic and proprietary injectable, intranasal, inhalation, and insulin active pharmaceutical ingredients. The company’s operations are divided into the Finished Pharmaceutical Products and Active Pharmaceutical Ingredients segments.
8. Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) is one of the best drug stocks to buy according to analysts. On April 17, UBS initiated coverage of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) with a Buy rating and set a $19 price target. The firm told investors in a research note that the recent share selloff on the macro environment offers an attractive entry point for the company’s “best-in-group growth profile”, adding that it believes the stock’s valuation suggests the market is discounting only modest and gradual revenue growth. UBS further stated that it believes that Amneal Pharmaceuticals’ specialty growth, driven by its Parkinson’s products and emerging franchises, warrants a premium multiple.
In a separate development, Amneal Pharmaceuticals, Inc. announced on April 13 that it entered into a definitive agreement to acquire 100% of Kashiv BioSciences, LLC. The transaction has consideration that includes $375 million of cash and $375 million of equity payable at closing. It also includes up to $350 million in potential payments based on the attainment of certain regulatory milestones, the funding of operations through closing, and potential royalties based on commercial milestones.
Amneal Pharmaceuticals, Inc. is a medicine company that provides pharmaceuticals, with its product portfolio including generics, specialty, biosciences, and a product catalog. The company’s operations are divided into the following segments: Generics, Specialty, and AvKARE.
7. ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) is one of the best drug stocks to buy according to analysts. ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) announced on April 20 the launch of Pimozide Tablets 1 mg and 2 mg, with the Pimozide Tablets being the generic version of the reference listed drug (RLD) Orap®. The company reported that the US annual sales for Pimozide Tablets totaled approximately $3.1 million, based on February 2026 moving annual total (MAT) IQVIA data. Nikhil Lalwani, President and Chief Executive Officer of ANI Pharmaceuticals, Inc., stated that the company is excited to “bring limited competition products to market” while continuing to offer generic alternatives to its patients and customers.
In another development, ANI Pharmaceuticals, Inc. announced the launch of Carbamazepine Extended-Release Capsules, 100 mg, 200 mg, and 300 mg on April 13. The company stated that its Carbamazepine Extended-Release Capsules are the generic version of the reference listed drug (RLD) Carbatrol®. It further reported that the US annual sales for Carbamazepine Extended-Release Capsules totaled approximately $65 million, based on February 2026 moving annual total (MAT) IQVIA data.
ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company that develops, manufactures, and markets branded and generic prescription pharmaceuticals. The company’s operations are divided into the Generics, Established Brands, and Other, and Rare Disease segments.
6. Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA)
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) is one of the best drug stocks to buy according to analysts. Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) announced its fiscal Q1 2026 financial results on April 28 and also provided updates regarding its recent portfolio execution. The company reported that net product revenue for ARCALYST® in fiscal Q1 2026 reached $214.3 million, representing 56% year-over-year growth. The company experienced growth in both new and repeat prescribers as fiscal Q1 progressed, which offered momentum for its ARCALYST franchise for the rest of the year. Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) thus raised its 2026 ARCALYST net sales guidance to between $930 and $945 million from between $900 and $920 million. Total revenue for fiscal Q1 rose to $214.3 million, compared to $137.8 million for the first quarter of 2025.
The company further reported that the KPL-387 Phase 2 recurrent pericarditis data is expected in the second half of 2026, with the Phase 3 pivotal trial expected to initiate by the end of the year. In addition, management stated that the fiscal Q1 2026 cash balance grew to $468.1 million.
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) is a commercial-stage biopharmaceutical company that discovers, acquires, develops, and commercializes therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs.
5. BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX)
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is one of the best drug stocks to buy according to analysts. On April 7, RBC Capital lifted the price target on BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) to $14 from $13 while maintaining an Outperform rating on the shares. The rating update came as part of a broader research note by the firm previewing fiscal Q1 results in Biotech. It told investors in the research note that seasonal headwinds around gross/net, reimbursement resets, and fewer selling days may be exacerbated in fiscal Q1 by weather impact, especially for launching and in-clinic products. However, it also stated that the robust return of M&A, coupled with clarity on limited tariff/Most Favored Nation drug pricing impacts, could help offset both this and broader macro volatility while keeping sector perceptions favorable.
For additional reference, in its full year 2025 results, BioCryst Pharmaceuticals, Inc. reported ORLADEYO® net revenue of $601.8 million, up 38% year-over-year. It also maintained full-year 2026 ORLADEYO revenue guidance between $625 and $645 million.
BioCryst Pharmaceuticals, Inc. is a biotechnology company that provides structure-guided drug design to develop oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases.
4. Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is one of the best drug stocks to buy according to analysts. On April 22, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced the first presentation of new two-year data from the Phase 3 CAHtalyst® Adult study exhibiting sustained, substantial reductions in glucocorticoid (GC) doses in adults with classic congenital adrenal hyperplasia treated with CRENESSITY®. Management reported that around 70% of patients attained GC doses within the physiologic range, with the data building upon the previously reported one-year results.
Presented at the American Association of Clinical Endocrinology 2026 Annual Meeting in Las Vegas, Neurocrine Biosciences, Inc. further reported that around 75% of patients originally taking dexamethasone transitioned off this treatment, allowing a more physiologic glucocorticoid regimen without compromising androgen control. It further stated that the findings bolster “durable efficacy and a favorable long‑term safety profile in the largest interventional trial to date conducted in classic congenital adrenal hyperplasia”.
In a separate development, RBC Capital cut the price target on Neurocrine Biosciences, Inc. to $176 from $177 and reaffirmed an Outperform rating on the shares as part of its broader research note previewing Q1 results in Biotech.
Neurocrine Biosciences, Inc. is a biopharmaceutical company with a focus on neuroscience. It is involved in the research and development, sale, and commercialization of pharmaceuticals that treat neuroendocrine, neurological, and neuropsychiatric disorders. The company’s product portfolio includes treatments for chorea associated with Huntington’s disease, tardive dyskinesia, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids.
3. Zoetis Inc. (NYSE:ZTS)
Zoetis Inc. (NYSE:ZTS) is one of the best drug stocks to buy according to analysts. On April 21, Zoetis Inc. (NYSE:ZTS) announced that it is expanding the capabilities of Vetscan OptiCell, which is its cartridge-based, artificial intelligence-powered hematology analyzer. The expansion marks the next step in the platform’s evolution, with the company stating that the update would make Vetscan OptiCell the first point-of-care hematology analyzer to offer cellular hemoglobin concentration mean (CHCM).
In a separate development, Citi initiated coverage of Zoetis Inc. with a Buy rating on April 15 and set a price target of $145. The firm also opened an “upside 90-day catalyst watch” on the company, stating that Solensia will return to growth in fiscal 2026. Citi launched the animal health and dental sectors with a “cautiously optimistic” view, stating that it favors the animal health group and believes that the “humanization” pet trend is real and should drive more spending. Zoetis Inc. is its top pick. The firm also stated that it sees the weak macro backdrop pressuring the dental sector, and it anticipates a trade-down to lower-cost implants and orthodontics. It added that its top dental pick is Henry Schein.
Zoetis Inc. is a global animal health company that focuses on the discovery, development, manufacture, and commercialization of vaccines, medicines, biodevices, genetic tests, diagnostic products, and precision animal health. Its operations are divided into the United States and International segments.
2. AbbVie Inc. (NYSE:ABBV)
AbbVie Inc. (NYSE:ABBV) is one of the best drug stocks to buy according to analysts. AbbVie Inc. (NYSE:ABBV) announced on April 27 the submission of an application to the U.S. Food and Drug Administration (FDA) seeking approval for SKYRIZI® for subcutaneous induction for the treatment of adult patients with moderately to severely active Crohn’s disease. Management stated that the application is supported by the recently shared positive data from the Phase 3 AFFIRM study evaluating the efficacy and safety of risankizumab SC as an induction treatment in adult patients with moderately to severely active CD. This includes both those with and without prior advanced therapy failure.
In a separate development, AbbVie Inc. received a rating update from Piper Sandler on April 23. The firm cut the price target on AbbVie Inc. to $294 from $299 while reaffirming an Overweight rating on the shares. The rating update came ahead of the quarterly results, with the firm saying that the company has become a bit controversial. Despite that, Piper is making a case for why there is no need for investors to worry, as the primary worry on AbbVie Inc., as seen by the firm, is driven in part by the rollout of oral IL-23-directed treatment Icotyde by Johnson & Johnson in the psoriasis setting, along with how it could impact the trajectory of Skyrizi.
AbbVie Inc. is a research-based pharmaceutical company that develops and sells products to treat chronic diseases in oncology, gastroenterology, rheumatology, dermatology, virology, and various other serious health conditions.
1. Eli Lilly and Company (NYSE:LLY)
Eli Lilly and Company (NYSE:LLY) is one of the best drug stocks to buy according to analysts. Eli Lilly and Company (NYSE:LLY) announced on April 27 the signing of a definitive agreement for it to acquire Ajax. Ajax is a biopharmaceutical company that develops next-generation JAK inhibitors for patients with myeloproliferative neoplasms, and its lead asset, AJ1-11095, is an investigational, once-daily oral, first-in-class Type II JAK2 inhibitor currently being evaluated in a Phase 1 clinical trial, AJX-101, in patients with myelofibrosis who have previously been treated with a Type I JAK2 inhibitor.
In a separate development, Reuters reported on April 24 that, according to analysts citing IQVIA data, Eli Lilly and Company’s newly launched oral weight loss drug, branded as Foundayo, was prescribed 3,707 times in the United States in the second week following its launch earlier in the month. The pill had 1,390 prescriptions in its first week of launch. Reuters provided additional perspective in the context of Eli Lilly and Company’s rival Novo Nordisk’s Wegovy pill. It reported that Wegovy has been on the market since January and had 3,071 prescriptions in its first week, followed by 18,410 prescriptions in the second week.
Eli Lilly and Company develops, manufactures, discovers, and sells pharmaceutical products. These products span oncology, diabetes, immunology, neuroscience, and other therapies.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
